Avalon Pharmaceuticals Announces Small Molecule Drug Discovery Program
News Sep 14, 2005
Avalon Pharmaceuticals, Inc. has announced that it is entering into collaboration with Novartis to discover small molecule therapeutic compounds targeted against a pathway selected by Novartis.
Avalon will use its AvalonRx® drug discovery engine in this pilot study to identify hits from compounds in Novartis' chemical library.
Novartis will be responsible for lead optimization, preclinical and clinical testing of any resulting product candidates, as well as all future development and sales and marketing activities.
Under the terms of the agreement, Avalon will receive an upfront payment, research support, and milestone payments.
"We are very pleased to enter this drug discovery collaboration with one of the top pharmaceutical companies in the world," stated Ken Carter, Ph.D., CEO of Avalon.
"As our second chemical genomics deal since June, this collaboration is further validation of the potential value of our AvalonRx® drug discovery engine."
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018